Vepdegestrant Tablets 100 mg, 200 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 200 mg
Reference Brands: Veppanu
Category: Oncology Cancer Care
Vepdegestrant (Veppanu, Arvinas) is a once-daily tablet for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, approved by the US FDA in May 2026. It is the first approved PROTAC protein degrader. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.
Manufacture or export Vepdegestrant Tablets? List it or send an offer →
Product Description:
Vepdegestrant is a PROTAC (proteolysis-targeting chimera). One end of the molecule binds the oestrogen receptor and the other recruits the cell's own protein-disposal machinery, so the receptor is tagged and destroyed rather than just blocked. It is the first medicine of this type to be approved, and it works against the ESR1-mutant receptors that make breast cancer resistant to aromatase inhibitors.
The US FDA approved vepdegestrant as Veppanu in May 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one endocrine therapy. An ESR1 mutation test is needed before treatment. It is taken as a 200 mg tablet once a day.
Sourcing and licensing notes. Vepdegestrant is patented and there is no generic. We confirm registration status for each destination before quoting. We handle authorised-supply enquiries and connect developers and licensees interested in the molecule and the PROTAC class ahead of patent expiry.
How Vepdegestrant Tablets is supplied today, and licensing ahead of patent expiry
Where vepdegestrant is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Veppanu · FDA · May 2026 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one endocrine therapy.
Veppanu, from Arvinas. The US FDA approved it in May 2026.
A molecule that makes the cell destroy a target protein instead of just blocking it. Vepdegestrant destroys the oestrogen receptor and is the first PROTAC to be approved.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Relacorilant Capsules
Strength:
25 mg, 100 mg
Form: Soft capsules
Reference Brands: Lifyorli
View DetailsSonrotoclax Tablets
Strength:
1 mg, 5 mg, 20 mg, 80 mg
Form: Tablets
Reference Brands: Beqalzi
View Details
Regorafenib
Strength:
40 mg, 80 mg, 120 mg, 160 mg
Form: Tablets
Reference Brands: Stivarga (USA/EU)
View Details
Histrelin Acetate
Strength:
50 mg
Form: Subcutaneous implant
Reference Brands: Vantas (USA), Supprelin LA (USA)
View Details
Usually answered within 48 hours | GMP documents shared before you commit
